BackPrelude Therapeutics Overview
Prelude Therapeutics Inc

Prelude Therapeutics Target Price

Analysts' average 12-month price target for Prelude Therapeutics is $8.

Get informed when a big investor buys or sells

+ Follow

Share Price

$4.52

Average Target Price

$8.0077% upside

1 analysts in the last 4 months

High: $8 | Low: $8

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-04-27H.C. Wainwright$877% upsideOpen
2024-09-10H.C. WainwrightRobert Burns$510.6% upsideOpen
2024-06-20BarclaysPeter Lawson$333.6% downsideOpen
2024-03-13JMP SecuritiesReni Benjamin$754.9% upsideOpen
2022-11-17H.C. Wainwright$15231.9% upsideOpen
2022-11-15Morgan Stanley$10121.2% upsideOpen

Prelude Therapeutics (PRLD) FAQ

Prelude Therapeutics (PRLD) currently reports a target price of $8. Use the charts on this page to explore Prelude Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for Prelude Therapeutics is $8, about 77.0% upside from the current share price of $4.52. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $8, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Prelude Therapeutics, and consider following PRLD for alerts when major investors trade the stock.

Prelude Therapeutics is classified in the Healthcare sector. On target price, it currently shows $8. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PRLD with unrelated industries.